Key Takeaways
- • Evvy, a precision medicine company focused on women's health, secured an oversubscribed $40 million Series B round led by Catalio Capital Management, bringing total institutional backing from 12+ investors including LabCorp Venture Fund and General Catalyst.
- • The company has built the world's largest proprietary clinical-grade dataset on the vaginal microbiome and developed EvvyAI, a machine learning engine designed to interpret large-scale biological data and transform patient care delivery across women's health.
- • Evvy's CLIA-certified, CLEP-approved Vaginal Health Test identifies 700+ microbes via at-home swab and currently serves 100,000+ patients with personalized treatment pathways for vaginal infections, fertility, menopause, and related conditions.
- • Series B capital will fund validation of AI-driven diagnostic and care models, with initial focus on fertility applications, leveraging 15+ peer-reviewed publications demonstrating test methodology validation and improved patient outcomes.
- • New investors joining the round include Rethink Impact, Muse Capital, and Alumni Ventures, signaling institutional confidence in the fertility and women's health diagnostic market opportunity.
Summary
Evvy, a precision medicine company specializing in women's health diagnostics, announced the close of a $40 million Series B funding round led by Catalio Capital Management. The oversubscribed round reflects investor confidence in the company's proprietary biomarker discovery platform and clinical-grade dataset development. The Series B adds four new institutional investors—Catalio Capital Management, Rethink Impact, Muse Capital, and Alumni Ventures—while maintaining support from existing backers including LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures.
Since its 2021 founding, Evvy has assembled what the company characterizes as the world's largest proprietary dataset focused on the vaginal microbiome and associated women's health outcomes. The centerpiece of this data infrastructure is EvvyAI, a machine learning engine designed to interpret large-scale biological data and generate actionable insights for clinical care. The Vaginal Health Test, Evvy's flagship diagnostic product, holds CLIA certification and CLEP approval as the sole mNGS-based assay capable of identifying 700+ individual microbes through a single at-home swab. The test currently serves over 100,000 patients and addresses clinical needs across vaginal infections, fertility, menopause, and related conditions.
The Series B proceeds will fund validation studies for a new generation of AI-driven diagnostic and treatment models across the women's health spectrum, with immediate focus on fertility applications. Evvy's clinical validation pipeline already includes 15+ peer-reviewed publications and abstracts, establishing methodology validation and demonstrating measurable improvements in patient outcomes. The capital injection positions the company to expand its clinical evidence base and scale the precision treatment pathways that accompany its diagnostic offerings, directly supporting its stated mission to close the gender health gap through novel biomarker discovery.
Since its 2021 founding, Evvy has assembled what the company characterizes as the world's largest proprietary dataset focused on the vaginal microbiome and associated women's health outcomes. The centerpiece of this data infrastructure is EvvyAI, a machine learning engine designed to interpret large-scale biological data and generate actionable insights for clinical care. The Vaginal Health Test, Evvy's flagship diagnostic product, holds CLIA certification and CLEP approval as the sole mNGS-based assay capable of identifying 700+ individual microbes through a single at-home swab. The test currently serves over 100,000 patients and addresses clinical needs across vaginal infections, fertility, menopause, and related conditions.
The Series B proceeds will fund validation studies for a new generation of AI-driven diagnostic and treatment models across the women's health spectrum, with immediate focus on fertility applications. Evvy's clinical validation pipeline already includes 15+ peer-reviewed publications and abstracts, establishing methodology validation and demonstrating measurable improvements in patient outcomes. The capital injection positions the company to expand its clinical evidence base and scale the precision treatment pathways that accompany its diagnostic offerings, directly supporting its stated mission to close the gender health gap through novel biomarker discovery.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.